List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Electronic Discovery Market Size, Share, Growth, Trends and Forecast (2019 – 2024)
| Information & Communications Technology | Published by: Mordor Intelligence | Market: |
| 120 pages | Published: 12-06-2019 |
- Information & Communications Technology
- Mordor Intelligence
- 120 pages
- Published: 12-06-2019
Market Overview
With the evolution of a digital universe and the availability of faster bulk storage devices, electronic information and data constitute a factor that companies are increasingly relying on, owing to the lower maintenance costs of documents and data production across the world. This has led to the challenges faced by the enterprises, in terms of collection and storage of digital data, to be used in litigation and regulatory processes. To manage this electronic data, electronic discovery (e-discovery) solutions are being deployed.
E-discovery solutions automate and facilitate the e-discovery process, which includes the identification, preservation, collection, processing, review, analysis, and production of digital data in support of the common law discovery process, in litigation or other investigative proceedings.
According to the RAND Corporation, the majority of Fortune 1000 corporations now spend an estimated USD 5 million to USD 10 million, annually, on e-discovery. Moreover, by 2020, it is expected that the data created and copied annually will reach approximately 50 zettabytes (50 trillion gigabytes), further generating a need for e-discovery solutions.
With the evolving technological world and the global market, there is an intense competition among companies. With this comes the risk of being targeted by their competitors, through industrial espionage, spreading false information, and leaking confidential information, to damage the company’s brand value in the market.
Scope of the Report
Electronic discovery is the electronic aspect of recognizing, collecting and producing electronically stored information (ESI) in response to a request for production in a lawsuit or investigation. ESI comprises, but is not limited to, emails, documents, presentations, databases, voicemail, audio and video files, and social media.
Key Market Trends
The Rising Adoption of e-Discovery Services by Government Sector
Government departments across the world have recognized the value of electronic records for various investigations. Various institutions, such as The Civil Division of the United States Department of Justice, have been insisting on the impotence of such electronic records.
Governments have various regulations to be checked, when it comes to the establishment of new companies, etc. The recent case of “Paradise papers” emphasizes the need for e-discovery in governmental institutes for finding various felonies committed, such as money laundering, tax frauds, etc.
Cases in the past faced by the US government, such as accusations against 19 defendants participating in a criminal conspiracy, has been side-tracked. This has been done by providing about 200 TB of data, out of which only 8 TB of data was relevant to the case. Even the 8TB data was not in a relevant format to search. Such cases indicate the importance of e-discovery for governments.
Federal legal professionals are yet to use e-discovery extensively. It has been estimated that only 38% of them can show accurate, trustworthy information. Government professionals have less confidence in e-discovery software. But, with the growing electronically stored information (ESI), this is bound to change.
North America Expected to Remain the Largest Market for Electronic Discovery Solutions
North America is the largest market for electronic discovery solutions in the world. Out of all the 50 states in the country, 49 states have already enacted e-discovery rules. Hawaii, being the youngest of all the states, has not yet appeared on the list and is making its efforts to establish e-discovery rules. California has most recently regulated e-discovery laws in the country. In 2009, after the California Code of Civil Procedure was amended by the Electronic Discovery Act to address the discovery of electronically stored information, further amendments have taken places even in 2012 that became effective in 2013.
This makes the State of California have the most updated laws on e-discovery. E-discovery solutions are put to work when situations like lawsuits, internal investigation, mergers & acquisitions, and data breach events occur. In the case of the United States, lawsuits and data breach incidents prove to be the trigger in most of the cases.
According to the data from the Administrative Office of the US Courts, 2017, the US courts of appeals filings rose 10% from 2016. The bankruptcy appellate panels reported that filings rose 1% while the filings for the Federal Circuit rose 11%. In the US district courts, filings of civil cases also rose by 6% in 2017 from 2016. This scenario, with highly penetrated electronic discovery laws in the country, is enabling the use of e-discovery solutions to mine the required data and present it to the court.
Competitive Landscape
The eDiscovery Market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. These major players with a prominent share in the market are focusing on expanding their customer base across foreign countries. These companies are leveraging on strategic collaborative initiatives to increase their market share and increase their profitability. In March 2017, IBM revealed planned on updating the discovery service of its artificial intelligence-powered platform Watson with an expansion of its eDiscovery and business research technology. Watson Discovery Service enabled developers to implement a machine learning model in their search tools, which allowed the tools to understand how certain language terms are related on a deeper level. The service enabled developers to create search and e-discovery tools using Watson’s technology which comprehended language and data on an almost human level.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
2.1 Study Assumptions
2.2 Analysis Methodology
2.3 Research Phases
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Introduction to Market Drivers and Restraints
4.3 Market Drivers
4.3.1 Increase in Lawsuits
4.3.2 Digitization of Information
4.3.3 Need for Securing Information
4.4 Market Restraints
4.4.1 Language Translation
4.4.2 Higher Costs of E-discovery Solutions
4.5 Value Chain Analysis
4.6 Industry Attractiveness Porters Five Force Analysis
4.6.1 Threat of New Entrants
4.6.2 Bargaining Power of Buyers/Consumers
4.6.3 Bargaining Power of Suppliers
4.6.4 Threat of Substitute Products
4.6.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Service
5.1.1 Professional Service
5.1.2 Managed Service
5.2 By Software
5.3 By Deployment
5.3.1 SaaS
5.3.2 On-premise
5.3.3 Hosted
5.4 By End User
5.4.1 Government (Federal Agencies)
5.4.2 Energy & Utility
5.4.3 IT and Telecommunication
5.4.4 Transportation & Logistics
5.4.5 Healthcare
5.4.6 Media & Entertainment
5.4.7 BFSI
5.4.8 Other End Users
5.5 Geography
5.5.1 North America
5.5.1.1 US
5.5.1.2 Canada
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 UK
5.5.2.3 France
5.5.2.4 Russia
5.5.2.5 Italy
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 South Korea
5.5.3.5 Australia
5.5.3.6 Rest of Asia-Pacific
5.5.4 Latin America
5.5.4.1 Brazil
5.5.4.2 Argentina
5.5.4.3 Mexico
5.5.4.4 Rest of Latin America
5.5.5 Middle East and Africa
5.5.5.1 UAE
5.5.5.2 Saudi Arabia
5.5.5.3 Israel
5.5.5.4 Rest of Middle East and Africa
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 IBM Corporation
6.1.2 Relativity ODA LLC
6.1.3 AccessData Group Inc.
6.1.4 ZyLAB, Inc.
6.1.5 Xerox Corporation
6.1.6 Logikcull.com
6.1.7 Guidance Software Inc.
6.1.8 Micro Focus International plc
6.1.9 Exterro Inc.
6.1.10 Driven Inc
6.1.11 Nuix Pty Ltd
6.1.12 Veritas Technology LLC
6.1.13 CloudNine
6.1.14 Kroll Ontrack LLC
6.1.15 FTI Consulting Inc
6.1.16 Microsoft Corporation
6.1.17 Catalyst Repository Systems Inc.
6.1.18 Everlaw Inc
6.1.19 Deloitte Touche Tohmatsu Limited
7 INVESTMENT ANALYSIS
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Service
Professional Service
Managed Service
By Software
By Deployment
SaaS
On-premise
Hosted
By End User
Government (Federal Agencies)
Energy & Utility
IT and Telecommunication
Transportation & Logistics
Healthcare
Media & Entertainment
BFSI
Other End Users
Geography
North America
US
Canada
Europe
Germany
UK
France
Russia
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Latin America
Brazil
Argentina
Mexico
Rest of Latin America
Middle East and Africa
UAE
Saudi Arabia
Israel
Rest of Middle East and Africa
Dashboard Camera Market – Growth, Trends, and Forecast (2019 – 2024)
| Electronics | Published by: Mordor Intelligence | Market: |
| 120 pages | Published: 12-06-2019 |
- Electronics
- Mordor Intelligence
- 120 pages
- Published: 12-06-2019
Market Overview
The global dashboard camera market was valued at USD 2519 million in 2018, and it is expected to register a CAGR of 15.4%, during the forecast period of 2019-2024. The market studied has expanded rapidly over the last few years, due to a considerable rise in the number of accidents and thefts, which have led to various governments mandating the installation of dashcams.
The expansion of the market studied was further supported by the increase in automobile sales, globally. As the automotive sector is evolving consistently, integration of dashcams has become a prominent trend, worldwide.
Driving assistance systems have gained popularity recently, owing to the drastic rise in the number of accidental fatalities that have been reported in the last decade. The demand for better assistance systems to categorically judge imminent dangers, and guide drivers has emerged as viable product in the automotive sector.
Several insurance companies are contributing to the increase in dashboard camera sales by offering discounts on car insurance premiums to customers. The demand for dashcams is also increasing, as it can reduce insurance frauds or claims by capturing on video events
.
Scope of the Report
Dashboard Cameras are onboard cameras that continuously record the view through a vehicle’s front windscreen and sometimes rear or other windows. The important benefits of vehicle dash cameras are its accident recording capabilities. It helps to capture vehicle collations on video which ensures that there is always a witness around. Besides, many people have used accident footage to prove that they were not wrong. Dashcams are also placed on truck’ dashboard which help to record front facing videos. Besides, advanced dash cams can record rear views and some are equipped with specialized sensors to support more effective nigh time recordings.
Key Market Trends
Dual-channel Cameras to Witness Major Growth
Multi-lens dashboard cameras represent a lucrative segment to invest in, for dashboard camera manufacturers. There has been an increasing preference for dual-channel dashboard cameras, over single-channel dashboard cameras.
These cameras are gaining popularity among private and commercial vehicle owners. Dual-channel dash cam systems comprise two cameras with high-resolution feed, for front and rear video recording.
Companies are continuously innovating, to develop their offerings and leverage this opportunity. For instance, Thinkware launched a two-channel (2CH) dashcam F200 that records in full HD 1080p with wide dynamic range (WDR) and offers 720p HD at the rear. It also has a built-in Wi-Fi functionality, which allows drivers to connect the dash cam directly to their smartphone, to adjust settings and easily download footage.
China to Witness Highest Growth
China is expected to overtake the United States as the world’s largest premium car market, creating a significant potential for the growth of the market studied. The Chinese automotive industry is expected to witness rapid technological evolution over the next few years, owing to the ongoing safety trend that is evident in North America and Europe. Particularly in the dashcam market, the country witnessed a 20% rise in sales, in recent years, due to increasing demand from insurance frauds. While the adoption of normal dashcams in the country is high, the manufacturers in the country are providing more enhanced solutions, like modern cameras equipped with Wi-Fi, ADAS, and real streaming media mirror.
Competitive Landscape
The dashboard camera market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. These major players with a prominent share in the market are focusing on expanding their customer base across foreign countries. These companies are leveraging on strategic collaborative initiatives to increase their market share and increase their profitability. In Oct 2017, Papago introduced new dashcams – Gosafe S37, Gosafe S780, and Papago Ray – at the world’s biggest automotive products show, SEMA. Jan 2018, Garmin announced the launch of Garmin Speak Plus with Amazon Alexa, by adding a built-in dash camera to its innovative Garmin Speak.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Industry Attractiveness Porter’s Five Force Analysis
4.2.1 Threat of New Entrants
4.2.2 Bargaining Power of Buyers/Consumers
4.2.3 Bargaining Power of Suppliers
4.2.4 Threat of Substitute Products
4.2.5 Intensity of Competitive Rivalry
4.3 Industry Value Chain Analysis
4.4 Introduction to Market Drivers and Restraints
4.5 Market Drivers
4.5.1 Increase in the Automobile Sales
4.5.2 Favorable Insurance Policies
4.5.3 Increase in the Number of Road Accidents and Thefts
4.5.4 Favorable Dashboard Camera Installation Mandates
4.6 Market Restraints
4.6.1 Reliability and Privacy Issues
4.6.2 Laws Restricting the Use of Dashcams in Some Countries
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Basic
5.1.2 Smart
5.2 By Product Type
5.2.1 Single-channel
5.2.2 Dual-channel
5.2.3 Rear-view
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Russia
5.3.2.5 Italy
5.3.2.6 Spain
5.3.2.7 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 India
5.3.3.2 China
5.3.3.3 Japan
5.3.3.4 South Korea
5.3.3.5 Rest of Asia-Pacific
5.3.4 Latin America
5.3.4.1 Argentina
5.3.4.2 Brazil
5.3.4.3 Mexico
5.3.4.4 Rest of Latin America
5.3.5 Middle East and Africa
5.3.5.1 Saudi Arabia
5.3.5.2 South Africa
5.3.5.3 UAE
5.3.5.4 Rest of Middle East and Africa
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Garmin Ltd.
6.1.2 Panasonic Corporation
6.1.3 Aiptek Inc.
6.1.4 ABEO Company Co. Ltd
6.1.5 Harman International Industries, Inc.
6.1.6 DOD Tech
6.1.7 Papago Inc.
6.1.8 Steelmate Automotive (UK) Ltd
6.1.9 HP Development Company LP
6.1.10 LG Electronics Inc.
7 INVESTMENT ANALYSIS
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technology
Basic
Smart
By Product Type
Single-channel
Dual-channel
Rear-view
Geography
North America
US
Canada
Europe
Germany
UK
France
Russia
Italy
Spain
Rest of Europe
Asia Pacific
India
China
Japan
South Korea
Rest of Asia-Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East and Africa
Saudi Arabia
South Africa
UAE
Rest of Middle East and Africa
Neuromodulation Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 111 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 111 pages
- Published: 12-06-2019
Market Overview
Neurological diseases are frequent in older adults, affecting around 55% of people age 55 and older. They are associated with a high risk for adverse health outcomes, including mortality, disability, institutionalization, and hospitalization. Degenerative diseases, like dementia and Parkinson’s disease, as well as strokes and headaches, are frequently encountered neurological diseases in elderly patients. Neuromodulation is an intracranial, electrical neuromodulation therapy that has FDA approval for the treatment for most of the neurological diseases such as bladder control, headache, tremors, chronic pain, stroke, minimally conscious state, and spinal cord injury, which are most commonly found in the elderly population. The proven efficacy and improving acceptance of this technology are expected to lead to the surge in the market demand during the forecast period.
Scope of the Report
Neuromodulators are a subset of neurotransmitter. Unlike neurotransmitters, the release of neuromodulators occurs in a diffuse manner. This means that an entire neural tissue may be subject to the neuromodulator’s action due to exposure. This, in turn, can tune the neural circuitry of an entire brain region and not just that of an individual neuron.
Key Market Trends
Spinal Cord Stimulation (SCS) Holds the Largest Market Share in the Internal Neuromodulation Type
The process of numbing/reducing chronic pain by passing continuous low voltage electric current to the spinal cord is referred to as spinal cord stimulation (SCS). The SCS devices are FDA approved and are the most widely accepted neurostimulation techniques across the world. These devices are of basic three types namely, rechargeable, conventional, and radiofrequency systems. SCS is used in neurological problems, such as nerve damage, arachnoiditis, failed-back surgery syndrome, neuropathy, complex regional pain syndrome, and neuritis. Along with the associated benefits and effectiveness, SCS also has some pitfalls, such as overstimulation, intermittent stimulation, lead dispositioning, and device malfunctioning. However, the benefits of the SCS outrank the pitfalls, thus boosting the segment’s growth over the forecast period.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America dominated the overall neuromodulation market with the United States accounting as the major contributor to the market. The presence of major market players and huge pharmaceutical and biopharmaceutical industries, coupled with the rising investments in the country for the adoption of advanced technologies, is expected to boost the regional growth of the market over the forecast period. In addition, the rising concern about the prevalence of neurological disorder and other associated disorders is stimulating the need for the adoption of neuromodulation techniques. Asia-Pacific, on the other hand, is expected to grow with the fastest growth rate over the forecast period.
Competitive Landscape
The major market players in the market include Medtronic PLC, Boston Scientific Corporation, St. Jude Medical Inc., Synapse Biomedical Inc., and Nevro Corporation, among others. The increasing innovation and rise in investment for various public and private organizations are expected to intensify the industry rivalry across the world.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Neurological Disorders
4.2.2 Increase in the Aging Population
4.2.3 Strong Product Pipeline
4.2.4 Expanded Target Applications and New Indications
4.2.5 Growing Investments
4.3 Market Restraints
4.3.1 Inconsistent Reimbursement Policies
4.3.2 Lack of Trained Professionals
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Internal Neuromodulation
5.1.1.1 Spinal Cord Stimulation (SCS)
5.1.1.2 Deep Brain Stimulation (DBS)
5.1.1.3 Vagus Nerve Stimulation (VNS)
5.1.1.4 Sacral Nerve Stimulation (SNS)
5.1.1.5 Gastric Electrical Stimulation (GES)
5.1.2 External Neuromodulation (Non-Invasive)
5.1.2.1 Transcutaneous Electrical Nerve Stimulation (TENS)
5.1.2.2 Transcranial Magnetic Stimulation (TMS)
5.1.2.3 Respiratory Electrical Stimulation (RES)
5.2 By Application
5.2.1 Parkinson’s disease
5.2.2 Depression
5.2.3 Chronic Pain
5.2.4 Failed Back Surgery
5.2.5 Ischemia
5.2.6 Urine Incontinence
5.2.7 Fecal Incontinence
5.2.8 Epilepsy
5.2.9 Gastroparesis
5.2.10 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Medtronic PLC
6.1.2 Boston Scientific Corporation
6.1.3 St. Jude Medical Inc.
6.1.4 Synapse Biomedical Inc.
6.1.5 Nevro Corporation
6.1.6 Neurosigma Inc.
6.1.7 Neuropace Inc.
6.1.8 Neuronetics Inc.
6.1.9 Cyberonics Inc.
6.1.10 BioControl Medical
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technology
Internal Neuromodulation
Spinal Cord Stimulation (SCS)
Deep Brain Stimulation (DBS)
Vagus Nerve Stimulation (VNS)
Sacral Nerve Stimulation (SNS)
Gastric Electrical Stimulation (GES)
External Neuromodulation (Non-Invasive)
Transcutaneous Electrical Nerve Stimulation (TENS)
Transcranial Magnetic Stimulation (TMS)
Respiratory Electrical Stimulation (RES)
By Application
Parkinson’s disease
Depression
Chronic Pain
Failed Back Surgery
Ischemia
Urine Incontinence
Fecal Incontinence
Epilepsy
Gastroparesis
Other Applications
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Asia-Pacific Diabetes Care Drugs Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 90 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 90 pages
- Published: 12-06-2019
Market Overview
The Asia-Pacific market for diabetes drugs is estimated to value USD 23.8 billion in 2019, and the market is expected to grow at the CAGR of 4.82%, during the forecast period.
Over the past few decades, Asian countries have witnessed a rapid increase in diabetes patients, especially those with type 2 diabetes. Developing countries have more than 70% of the global diabetes population.
The Asian population gets diabetes at a younger age in comparison to the Western population. The reason for this early diabetes development is the sudden change in lifestyle, due to rapid economic growth.
Asia contributes approximately 60% of the total diabetes patients in the world. The most obvious reason for this is that two of the most populated countries in the world are in Asia.
Scope of the Report
The Asia-Pacific diabetes drugs report covered by category (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), by segment (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, insulin biosimilars, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors), and by countries.
Key Market Trends
Oral Anti-Diabetes Drugs Take 67% of the Asia-Pacific Diabetes Drugs Market.
The use of oral anti-diabetes drugs is rising, due to the fact that new generation oral drugs, such as DPP-4 and SGLT-2, reduce the rate of CV risk in diabetes patients.
SGLT-2 and GLP-1 are linked to lowering the mortality rate more effectively than DPP-4 inhibitors.
Meglitinide and sulfonylureas are oral hypoglycemic drugs that directly arouse the discharge of insulin from pancreatic beta cells. They hold a significant market share, of 14.27% and 9.62%, respectively, in the Asia-Pacific anti-diabetics drugs market.
China and Japan Occupy more than a 50% Share in the Asia-Pacific Diabetes Drugs Market.
In the Asia-Pacific region, China and Japan have recognized as potential developing markets, due to the growing diabetic population in this region.
Japan is a mature market, with some associated challenges, like slow economic growth, the aging population, and increased competition. One particular challenge in this region is the growing preference for oral anti-diabetics among type-2 diabetic patients, thereby, leading to a negative insulin volume development.
China has the highest market share and is expected to grow with a steady CAGR of 4%. It also contributes 15% to the global diabetes drugs market.
The country is witnessing a significant increase in the number of generic drug manufacturers. Furthermore, the leading global players in the market studied are facing intense competition from the regional players.
Competitive Landscape
The Asia-Pacific diabetes care drugs market is highly fragmented, with a few major manufacturers gaining presence in major countries of the Asia-Pacific market, while the remaining market comprises other local or region-specific manufacturers.
Mergers and acquisitions that happened between players in the recent past helped companies strengthen their market presence, as well as driving innovations, helping the diabetes drugs market to increase in the Asia-Pacific region. For instance, Biocon has launched its insulin glargine biosimilar, in Japan and Malaysia, partnering with local manufacturers for further commercialization.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Oral Anti-diabetic Drugs
5.1.1.1 Biguanides (Value and Volume 2012-2024)
5.1.1.1.1 Metformin
5.1.1.2 Alpha – Glucosidase Inhibitors (Value and Volume 2012-2024)
5.1.1.2.1 Alpha – Glucosidase Inhibitors
5.1.1.3 Dopamine -D2 Receptor Agonist (Value and Volume 2012-2024)
5.1.1.3.1 Bromocriptin (Cycloset)
5.1.1.4 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
5.1.1.4.1 Invokana (Canagliflozin)
5.1.1.4.2 Jardiance (Empagliflozin)
5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)
5.1.1.4.4 Suglat (Ipragliflozin)
5.1.1.5 Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
5.1.1.5.1 Januvia (Sitagliptin)
5.1.1.5.2 Onglyza (Saxagliptin)
5.1.1.5.3 Tradjenta (Linagliptin)
5.1.1.5.4 Vipidia/Nesina (Alogliptin)
5.1.1.5.5 Galvus (Vildagliptin)
5.1.1.6 Sulfonylureas (Value and Volume 2012-2024)
5.1.1.6.1 Sulfonylureas
5.1.1.7 Meglitinides (Value and Volume 2012-2024)
5.1.1.7.1 Meglitinides
5.1.2 Insulin
5.1.2.1 Basal or Long-acting Insulins
5.1.2.1.1 Lantus (Insulin Glargine)
5.1.2.1.2 Levemir (Insulin Detemir)
5.1.2.1.3 Toujeo (Insulin Glargine)
5.1.2.1.4 Tresiba (Insulin Degludec)
5.1.2.1.5 Basaglar (Insulin Glargine)
5.1.2.2 Bolus or Fast-acting Insulins
5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)
5.1.2.2.2 Humalog (Insulin Lispro)
5.1.2.2.3 Apidra (Insulin Glulisine)
5.1.2.3 Traditional Human Insulins
5.1.2.3.1 Novolin/Actrapid/Insulatard
5.1.2.3.2 Humilin
5.1.2.3.3 Insuman
5.1.2.4 Biosimilar Insulins
5.1.2.4.1 Insulin Glargine Biosimilars
5.1.2.4.2 Human Insulin Biosimilars
5.1.3 Non-insulin Injectable Drugs
5.1.3.1 GLP-1 Receptor Agonists
5.1.3.1.1 Victoza (Liraglutide)
5.1.3.1.2 Byetta (Exenatide)
5.1.3.1.3 Bydureon (Exenatide)
5.1.3.1.4 Trulicity (Dulaglutide)
5.1.3.1.5 Lyxumia (Lixisenatide)
5.1.3.2 Amylin Analogue
5.1.3.2.1 Symlin (Pramlintide)
5.1.4 Combination Drugs
5.1.4.1 Insulin Combinations
5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)
5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
5.1.4.2 Oral Combination
5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)
5.2 Geography
5.2.1 Asia-Pacific
5.2.1.1 Australia (Value and Volume 2012-2024)
5.2.1.1.1 Oral Anti-diabetic Drugs
5.2.1.1.2 Insulin
5.2.1.1.3 Non-Insulin Injectable Drugs
5.2.1.1.4 Combination Drugs
5.2.1.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.2 China (Value and Volume 2012-2024)
5.2.1.2.1 Oral Anti-diabetic Drugs
5.2.1.2.2 Insulin
5.2.1.2.3 Non-Insulin Injectable Drugs
5.2.1.2.4 Combination Drugs
5.2.1.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.3 India (Value and Volume 2012-2024)
5.2.1.3.1 Oral Anti-diabetic Drugs
5.2.1.3.2 Insulin
5.2.1.3.3 Non-Insulin Injectable Drugs
5.2.1.3.4 Combination Drugs
5.2.1.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.4 Indonesia (Value and Volume 2012-2024)
5.2.1.4.1 Oral Anti-diabetic Drugs
5.2.1.4.2 Insulin
5.2.1.4.3 Non-Insulin Injectable Drugs
5.2.1.4.4 Combination Drugs
5.2.1.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.5 Japan (Value and Volume 2012-2024)
5.2.1.5.1 Oral Anti-diabetic Drugs
5.2.1.5.2 Insulin
5.2.1.5.3 Non-Insulin Injectable Drugs
5.2.1.5.4 Combination Drugs
5.2.1.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.6 Malaysia (Value and Volume 2012-2024)
5.2.1.6.1 Oral Anti-diabetic Drugs
5.2.1.6.2 Insulin
5.2.1.6.3 Non-Insulin Injectable Drugs
5.2.1.6.4 Combination Drugs
5.2.1.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.7 Philippines (Value and Volume 2012-2024)
5.2.1.7.1 Oral Anti-diabetic Drugs
5.2.1.7.2 Insulin
5.2.1.7.3 Non-Insulin Injectable Drugs
5.2.1.7.4 Combination Drugs
5.2.1.7.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.8 South Korea (Value and Volume 2012-2024)
5.2.1.8.1 Oral Anti-diabetic Drugs
5.2.1.8.2 Insulin
5.2.1.8.3 Non-Insulin Injectable Drugs
5.2.1.8.4 Combination Drugs
5.2.1.8.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.9 Thailand (Value and Volume 2012-2024)
5.2.1.9.1 Oral Anti-diabetic Drugs
5.2.1.9.2 Insulin
5.2.1.9.3 Non-Insulin Injectable Drugs
5.2.1.9.4 Combination Drugs
5.2.1.9.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.10 Vietnam (Value and Volume 2012-2024)
5.2.1.10.1 Oral Anti-diabetic Drugs
5.2.1.10.2 Insulin
5.2.1.10.3 Non-Insulin Injectable Drugs
5.2.1.10.4 Combination Drugs
5.2.1.10.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.11 Rest of Asia Pacific (Value and Volume 2012-2024)
5.2.1.11.1 Oral Anti-diabetic Drugs
5.2.1.11.2 Insulin
5.2.1.11.3 Non-Insulin Injectable Drugs
5.2.1.11.4 Combination Drugs
5.2.1.11.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Takeda
7.1.2 Pfizer
7.1.3 Eli Lilly
7.1.4 Janssen Pharmaceuticals
7.1.5 Astellas
7.1.6 Boehringer Ingelheim
7.1.7 Merck And Co.
7.1.8 AstraZeneca
7.1.9 Bristol Myers Squibb
7.1.10 Novartis
7.1.11 Sanofi
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Oral Anti-diabetic Drugs
Biguanides (Value and Volume 2012-2024)
Metformin
Alpha – Glucosidase Inhibitors (Value and Volume 2012-2024)
Alpha – Glucosidase Inhibitors
Dopamine -D2 Receptor Agonist (Value and Volume 2012-2024)
Bromocriptin (Cycloset)
Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas (Value and Volume 2012-2024)
Sulfonylureas
Meglitinides (Value and Volume 2012-2024)
Meglitinides
Insulin
Basal or Long-acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humilin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Non-insulin Injectable Drugs
GLP-1 Receptor Agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Combination Drugs
Insulin Combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combination
Janumet (Sitagliptin and Metformin HCl)
Geography
Asia-Pacific
Australia (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
China (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
India (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Indonesia (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Japan (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Malaysia (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Philippines (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
South Korea (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Thailand (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Vietnam (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Rest of Asia Pacific (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 100 pages
- Published: 12-06-2019
Market Overview
The SGLT2 inhibitors class of drugs include Jardiance, Fraxiga, Inovokana, and Suglat, among others. The demand for SGLT2 is expected to grow immensely, due to drugs like Jardiance and Farxiga.
The growing global type-2 diabetes population promotes the growth of SGLT2 drugs. The global SGLT2 market has a high potential for growth, due to the increasing number of diabetic patients and their need for drugs that help reduce high blood glucose levels, despite being on a medication regimen, such as metformin and insulin. SGLT2 serves this specific purpose.
The global market for SGLT2 is worth USD 6,573.8 million in 2019 and is expected to grow at CAGR of 16% by 2024.
Scope of the Report
The report includes a complete study of SGLT2 inhibitors, which include Invokana, Jardiance, Farxiga, and Suglat. The study is further divided into regional- and country-wise analyses, which cover all the drugs in the SGLT2 class.
Key Market Trends –
Jardiance is Leading the SGLT2 Market.
Jardiance, which was released globally in 2014, is a once-daily oral medication that is used to control blood glucose levels in people with type-2 diabetes.
Jardince is gaining sales when compared to Invokana, with patients preferring this drug, as it has a lower risk of cardiovascular diseases when compared to other SGLT2 drugs, by helping the kidneys remove glucose from the bloodstream.
Jardiance accounted for 41.5% of the sales in the global SGLT2 class of drugs in 2017. The market for Jardince was worth USD 2.5 billion in 2018 and is expected to grow at a CAGR of 15.78%, during the forecast period (2019-2024).
65% of the Market Share is Occupied by North America.
The growing global type-2 diabetes population promotes the growth of SGLT2 drugs. North America accounts for the highest type- 2 diabetic population. Prices are comparatively high in this region.
The North America SGLT2 market accounts for USD 3,471.5 million in 2018 and is expected to grow at CAGR of 15.5% by 2024.
In the United States, there are close to 900 lawsuits currently pending, regarding Invokana. Jardiance holds 50% of the market share in the US SGLT2 market.
Competitive Landscape
The SGLT2 market is highly consolidated, with a few significant manufacturers having a global market presence.
The joint ventures that occurred between players in the recent past have helped the companies strengthen their market presence. For example, Eli Lilly and Boehringer Ingelheim make Jardiance together, which is a very popular SGLT2 class drug.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Sodium – Glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
5.1.1.1 Invokana (Canagliflozin)
5.1.1.2 Jardiance (Empagliflozin)
5.1.1.3 Farxiga/Forxiga (Dapagliflozin)
5.1.1.4 Suglat (Ipragliflozin)
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume 2012-2024)
5.2.1.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.1.2 Canada (Value and Volume 2012-2024)
5.2.1.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.1.3 Rest of North America (Value and Volume 2012-2024)
5.2.1.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2 Europe
5.2.2.1 France (Value and Volume 2012-2024)
5.2.2.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.2 Germany (Value and Volume 2012-2024)
5.2.2.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.3 Italy (Value and Volume 2012-2024)
5.2.2.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.4 Spain (Value and Volume 2012-2024)
5.2.2.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.5 UK (Value and Volume 2012-2024)
5.2.2.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.6 Russia (Value and Volume 2012-2024)
5.2.2.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
5.2.2.7.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.3 Latin America
5.2.3.1 Mexico (Value and Volume 2012-2024)
5.2.3.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.3.2 Brazil (Value and Volume 2012-2024)
5.2.3.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.3.3 Rest of Latin America (Value and Volume 2012-2024)
5.2.3.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4 Asia-Pacific
5.2.4.1 Japan (Value and Volume 2012-2024)
5.2.4.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.2 South Korea (Value and Volume 2012-2024)
5.2.4.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.3 China (Value and Volume 2012-2024)
5.2.4.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.4 India (Value and Volume 2012-2024)
5.2.4.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.5 Australia (Value and Volume 2012-2024)
5.2.4.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.6 Vietnam (Value and Volume 2012-2024)
5.2.4.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.7 Malaysia (Value and Volume 2012-2024)
5.2.4.7.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.8 Indonesia (Value and Volume 2012-2024)
5.2.4.8.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.9 Philippines (Value and Volume 2012-2024)
5.2.4.9.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.10 Thailand (Value and Volume 2012-2024)
5.2.4.10.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.11 Rest of Asia-Pacific (Value and Volume 2012-2024)
5.2.4.11.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5 Middle East & Africa
5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)
5.2.5.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5.2 Iran (Value and Volume 2012-2024)
5.2.5.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5.3 Egypt (Value and Volume 2012-2024)
5.2.5.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5.4 Oman (Value and Volume 2012-2024)
5.2.5.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5.5 South Africa (Value and Volume 2012-2024)
5.2.5.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5.6 Rest of Middle & Africa (Value and Volume 2012-2024)
5.2.5.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Eli Lilly
7.1.2 Janssen Pharmaceuticals
7.1.3 Astellas
7.1.4 Boehringer Ingelheim
7.1.5 AstraZeneca
7.1.6 Bristol Myers Squibb
7.2 MARKET SHARE ANALYSIS
7.2.1 Eli Lilly
7.2.2 Janssen Pharmaceuticals
7.2.3 Astellas
7.2.4 Boehringer Ingelheim
7.2.5 AstraZeneca
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Sodium – Glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Geography
North America
United States (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Canada (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of North America (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Europe
France (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Germany (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Italy (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Spain (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
UK (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Russia (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Europe (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Latin America
Mexico (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Brazil (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Latin America (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Asia-Pacific
Japan (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
South Korea (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
China (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
India (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Australia (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Vietnam (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Malaysia (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Indonesia (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Philippines (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Thailand (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Asia-Pacific (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Middle East & Africa
Saudi Arabia (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Iran (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Egypt (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Oman (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
South Africa (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Middle & Africa (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Proton Pump Inhibitors Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 12-06-2019
Market Overview
The major factors for the growth of the proton pump inhibitors market include the increasing prevalence of gastroesophageal reflux disease (GERD) and the rising acceptance of novel drug delivery systems.
Gastroesophageal reflux disease is a chronic condition, where the stomach content comes back up into the esophagus resulting in either symptoms or complications. The most frequently reported symptoms of GERD are heartburn, a burning discomfort that begins behind the breastbone and radiates to the neck and throat, and acid regurgitation, which is characterized as a bitter, sour-tasting fluid.
In addition to the increase in prevalence, people with risk factors, such as obesity, tobacco use, and others, are also increasing in almost every part of the world. Obesity, which is the major risk factor of GERD, is increasing rapidly in developed countries, such as the United States, the United Kingdom, and others. The increasing prevalence of GERD, along with the growing risk factor population, is likely to lead to the growth in the demand for proton pump inhibitors, which in turn, will drive the market. Also, the increasing shift from prescription to OTC drugs is driving the proton pump inhibitors market.
Scope of the Report
As per the scope of the report, proton pump inhibitors (PPIs) are a group of drugs, whose main action is the long-lasting reduction of gastric acid production. They are the most potent inhibitors of acid secretion available. The market studied is further segmented on the basis of drug type and geography. The drug type segmentation includes OTC and prescription drugs.
Key Market Trends
Esomeprazole is Expected to Account for the Largest Market Share in Drug Type
Nexium is one among the leading revenue generating drugs globally, and it is used to treat the symptoms of GERD, heartburn, and other disorders involving excessive stomach acids. The drug was being sold as a prescriptive drug till before 28th March 2014, the date when FDA approved it as an OTC drug. The shift from being a prescription-only drug to being sold as an over-the-counter (OTC) drug is likely to be a major driving force for the sales of the drug in the near future. There are several benefits associated with OTC drugs, such as low price, enhanced accessibility, and no regular monitoring. As OTC drugs are sold without any prescription, the consumer need not go to any doctor for a prescription, which reduces the overall cost, and hence these drugs have the potential to increase their adoption rate. Accessibility is another vital factor for the consumption of any medicine, and better accessibility may definitely result in more revenue. However, OTC drugs have some disadvantages as well. As they can be purchased without any prescription, anyone can buy as many as they want and leave the scope for their overuse.
Additionally, there are several minor side effects, such as nausea, headaches, dry mouth, diarrhea, allergic reaction, and others, as well as some major side effects, such as kidney disease, dementia, and others associated with its use, which can affect the adoption rate, and hence can be the restraining factors for the growth of the market.
North America Accounted for the Largest Share in the Global Market
North America holds a major share in the proton pump inhibitors market and is expected to show a similar trend over the forecast period, without significant fluctuations. There is a rising prevalence of GERD in the United States, Canada, and Mexico. Furthermore, GERD affects up to 20% of adults in the United States, therefore making the disease an important concern. Proton pump inhibitors are the widely prescribed drugs, and increased PPI use has been observed in the US ambulatory settings. Furthermore, many firms are expected to spend heavily on promoting their brands. The widespread use of these has recently gained attention from the American Board of Internal Medicine’s campaign to promote the appropriate use of PPIs.
Competitive Landscape
The proton pump inhibitors market is a fragmented one, owing to the presence of various players in the market. The market players are focusing on acquiring the market share by focusing on aggressive advertisements and awareness programs among the patients. The major key players in the market include AstraZeneca, Bayer AG, Cadila Pharmaceuticals, GlaxoSmithKline PLC, Johnson & Johnson, and Pfizer.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Gastroesophageal Reflux Disease (GERD)
4.2.2 Rising Acceptance of Novel Drug Delivery Systems
4.3 Market Restraints
4.3.1 Increasing Use of Generic Products
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 OTC (Over-the-Counter) Drugs
5.1.1.1 Omeprazole
5.1.1.2 Lansoprazole
5.1.1.3 Esomeprazole
5.1.1.4 Other OTC Drugs
5.1.2 Prescription Drugs
5.1.2.1 Rabeprazole
5.1.2.2 Dexlansoprazole
5.1.2.3 Pantoprazole
5.1.2.4 Other Prescription Drugs
5.2 Geography
5.2.1 North America
5.2.1.1 US
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 UK
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca
6.1.2 Bayer AG
6.1.3 Cadila Pharmaceuticals
6.1.4 Eli Lilly and Company
6.1.5 Eisai Inc.
6.1.6 GlaxoSmithKline PLC
6.1.7 Johnson & Johnson
6.1.8 Pfizer Inc.
6.1.9 Santarus Inc.
6.1.10 Takeda Pharmaceuticals
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug Type
OTC (Over-the-Counter) Drugs
Omeprazole
Lansoprazole
Esomeprazole
Other OTC Drugs
Prescription Drugs
Rabeprazole
Dexlansoprazole
Pantoprazole
Other Prescription Drugs
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America